Search for a clinical trial
Other search option(s)
23 Result(s)
Recruiting trial
= 
; Ongoing trial
= 
; Funded by an IRDiRC member = 
; Member of a ERN = 
National clinical trial(s)
BELGIUM
OOST-VLAANDEREN
GENT
SUNFISH: A two-part seamless, multi-center randomized, placebo-controlled, double blind study to investigate the safety, tolerability, pharmacokinetics, pharmacodynamics and efficacy of RO7034067 in type 2 and 3 spinal muscular atrophy patients - BE
Ghent University Hospital - UZ Gent
NMRC UZ Gent
GERMANY
Baden-Württemberg
FREIBURG
Can treatment with human growth hormone increase strength in spinal muscular atrophy type II and III (phase II study)?
Zentrum für Kinder- und Jugendmedizin Freiburg
Klinik für Neuropädiatrie und Muskelerkrankungen
GERMANY
Baden-Württemberg
FREIBURG
NURTURE: An Open-Label Study to Assess the Efficacy, Safety, Tolerability, and Pharmacokinetics of Multiple Doses of ISIS 396443 Delivered Intrathecally to Subjects With Genetically Diagnosed and Presymptomatic Spinal Muscular Atrophy (Phase II) - DE
Zentrum für Kinder- und Jugendmedizin Freiburg
Klinik für Neuropädiatrie und Muskelerkrankungen
GERMANY
Bayern
MÜNCHEN
An Open-Label Extension Study for Patients With Spinal Muscular Atrophy Who Previously Participated in Investigational Studies of ISIS 396443 (Phase III) - DE
Friedrich-Baur-Institut
Friedrich-Baur-Institut an der Neurologischen Klinik und Poliklinik
GERMANY
Bayern
MÜNCHEN
OLEOS: Multicenter, Open-Label, Single Arm Study to Evaluate Long-term Safety, Tolerability, and Effectiveness of 10 mg/kg Olesoxime in Patients with SMA (Phase II)
Friedrich-Baur-Institut
Friedrich-Baur-Institut an der Neurologischen Klinik und Poliklinik
SPAIN
Andalucía
SEVILLA
SUNFISH: A two-part seamless, multi-center randomized, placebo-controlled, double blind study to investigate the safety, tolerability, pharmacokinetics, pharmacodynamics and efficacy of RO7034067 in type 2 and 3 spinal muscular atrophy patients (Phase II) - ES
Hospital Universitario Virgen del Rocío
Unidad de Neurología Pediátrica
SPAIN
Cataluña
BARCELONA
An Open-Label Extension Study for Patients With Spinal Muscular Atrophy Who Previously Participated in Investigational Studies of ISIS 396443 (Phase III) - ES
Hospital Universitari Vall d'Hebron
Área de Genética Clínica y Molecular
SPAIN
Cataluña
BARCELONA
SUNFISH: A two-part seamless, multi-center randomized, placebo-controlled, double blind study to investigate the safety, tolerability, pharmacokinetics, pharmacodynamics and efficacy of RO7034067 in type 2 and 3 spinal muscular atrophy patients (Phase II) - ES
Hospital Universitari Vall d'Hebron
Área de Genética Clínica y Molecular
SPAIN
Cataluña
ESPLUGUES DE LLOBREGAT
An Open-Label Extension Study for Patients With Spinal Muscular Atrophy Who Previously Participated in Investigational Studies of ISIS 396443 (Phase III) - ES
Hospital Sant Joan de Déu Barcelona
Unidad de Enfermedades Neuromusculares
SPAIN
Cataluña
ESPLUGUES DE LLOBREGAT
SUNFISH: A two-part seamless, multi-center randomized, placebo-controlled, double blind study to investigate the safety, tolerability, pharmacokinetics, pharmacodynamics and efficacy of RO7034067 in type 2 and 3 spinal muscular atrophy patients (Phase II) - ES
Hospital Sant Joan de Déu Barcelona
Servicio de Neurología
SPAIN
Madrid
ADDRESS: NOT PROVIDED - ES
The TOPAZ study: Phase 2 Active Treatment Study to Evaluate the Efficacy and Safety of SRK-015 in Patients with Later-Onset Spinal Muscular Atrophy - ES
Institution: Information not provided - ES
SPAIN
Madrid
MADRID
An Open-Label Extension Study for Patients With Spinal Muscular Atrophy Who Previously Participated in Investigational Studies of ISIS 396443 (Phase III) - ES
Hospital Universitario La Paz
Servicio de Neurología infantil
SPAIN
Madrid
MADRID
SUNFISH: A two-part seamless, multi-center randomized, placebo-controlled, double blind study to investigate the safety, tolerability, pharmacokinetics, pharmacodynamics and efficacy of RO7034067 in type 2 and 3 spinal muscular atrophy patients (Phase II) - ES
Hospital Universitario La Paz
Servicio de Neurología infantil
BELGIUM
ARRONDISSEMENT BRUSSELS-CAPITAL
BRUSSELS
SHINE: An Open-Label Extension Study for Patients With Spinal Muscular Atrophy Who Previously Participated in Investigational Studies of ISIS 396443 - BE
Erasme Hospital - ULB
Centre de Référence Neuromusculaire Erasme-HUDERF
BELGIUM
LIEGE
LIEGE
RAINBOWFISH: An Open-Label Study of Risdiplam in Infants With Genetically Diagnosed and Presymptomatic Spinal Muscular Atrophy - BE
Centre Hospitalier Régional de la Citadelle
Centre de Référence des Maladies Neuromusculaires (CRMN)
BELGIUM
OOST-VLAANDEREN
GENT
JEWELFISH: An Open-Label Study to Investigate the Safety, Tolerability, and Pharmacokinetics/Pharmacodynamics of RO7034067 in Adult and Pediatric Patients With Spinal Muscular Atrophy - BE
Ghent University Hospital - UZ Gent
NMRC UZ Gent
FRANCE
ILE-DE-FRANCE
PARIS
A Phase 3, Randomized, Double-blind, Sham-Procedure Controlled Study to Assess the Clinical Efficacy and Safety of ISIS 396443 Administered Intrathecally in Patients With Infantile-onset Spinal Muscular Atrophy - FR
CHU Paris Est - Hôpital d'Enfants Armand-Trousseau
Institut I-Motion - Centre de recherche pédiatrique en pathologies neuromusculaires
SPAIN
Madrid
ADDRESS: NOT PROVIDED - ES
DEVOTE: Escalating Dose and Randomized, Controlled Study of Nusinersen (BIIB058) in Participants With Spinal Muscular Atrophy - ES
Institution: Information not provided - ES
UNITED STATES
Washington
ADDRESS: NOT PROVIDED - US
A Phase 3, Randomized, Double-blind, Sham-Procedure Controlled Study to Assess the Clinical Efficacy and Safety of ISIS 396443 Administered Intrathecally in Patients With Infantile-onset Spinal Muscular Atrophy - US
Institution: Information not provided - US
FRANCE
ILE-DE-FRANCE
GARCHES
Long-Term Effect of LIAM (Lung Insufflation Assist Maneuver) on Respiratory Performance in Non-invasive Ventilated Patients Suffering From Neuromuscular Disease - FR
CHU Paris IdF Ouest - Hôpital Raymond Poincaré
Centre d'Investigation Clinique et Technologique 805 - CIC-IT de Garches
FRANCE
ILE-DE-FRANCE
GARCHES
Establishment of a Non-invasive and Indirect Measure of Volitional Pimax (PI MAX STIM) - FR
CHU Paris IdF Ouest - Hôpital Raymond Poincaré
Service de Physiologie-Explorations Fonctionnelles
Multinational clinical trial(s)
ITALY
LAZIO
ROMA
Phase II, multicenter, randomized, adaptive, double-blind, placebo controlled study to assess safety and efficacy of olesoxime (TRO19622) in 3-25 year old Spinal Muscular Atrophy (SMA) patients - coordination
IRCCS Ospedale Pediatrico Bambino Gesù - SEDE GIANICOLO
Ospedale Pediatrico Bambino Gesù
SWITZERLAND
Suisse Alémanique
BASEL